CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 23 enrolled
Drug / intervention
rice bran arabinoxylan compound (RBAC) +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02568787
NCT02568787N/ACompleted
CompareCT.gov

The Effect of an Enhanced Rice Bran Nutritional Supplement on Non-Alcoholic Fatty Liver Disease (NAFLD)

University of Miami·interventional·Posted Oct 6, 2015·Updated Jun 14, 2017

In Brief

A clinical study evaluating rice bran arabinoxylan compound (RBAC) and Placebo for Non-Alcoholic Fatty Liver Disease. Completed, enrolled 23 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the effects of Rice Bran Arabinoxylan Compound (RBAC) on outcome variables in persons with non-alcoholic fatty liver disease (NAFLD). This nutritional supplement is made from a water soluble extract of rice bran that has been partially hydrolyzed by the action of a natural enzyme complex extracted from Shiitake mushroom.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Alcoholic Fatty Liver Disease
CountriesUnited States
CollaboratorsDaiwa Health Development

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 6, 2015
Enrollment StartMay 1, 2016
Primary CompletionJun 10, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 10.7 years ago

Interventions

rice bran arabinoxylan compound (RBAC)dietary

Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.

Placebodietary

Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.